Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oncology Sciences Corp.

www.oncologysciences.com

Latest From Oncology Sciences Corp.

Oncology Sciences Corp.

Founded in close affiliation with Denver's AMC Cancer Research Center, Oncology Sciences Corp. is taking a natural approach to fighting prostate cancer. It is focusing on preclinical development of an endogenous angiogenesis inhibitor as well as other natural substances that work through anti-angiogenic and additional mechanisms.
BioPharmaceutical

Anti-Angiogenesis

Anti-angiogenesis as a treatment for cancer was hardly a new concept, even in 1998 when a New York Times article first put Judah Folkman's work on the public map. Although the hype has died away, the industrial machine of anti-angiogenesis has continued to roll on--as indicated by the start-up activity we describe in the following profiles.
BioPharmaceutical Regulation
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Oncology Sciences Corp.
  • Senior Management
  • Loretta Zapp, Pres. & CEO
    Will Wenmohs, CFO
    Lyndon C Johnson, VP, Sales & Mktg.
  • Contact Info
  • Oncology Sciences Corp.
    Phone: (512) 732-8300
    1250 Capital of Texas Hwy.
    Bldg. 1
    Austin, TX 78746
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register